Addiction-related outcomes of nicotine and alcohol co-use: new insights following the rise in vaping
Purpose Nicotine and alcohol-containing products are some of the most commonly used
substances of abuse and are both leading causes of preventable death. These substances …
substances of abuse and are both leading causes of preventable death. These substances …
Behavioral mechanisms underlying nicotine reinforcement
LE Rupprecht, TT Smith, RL Schassburger… - … of nicotine dependence, 2015 - Springer
Cigarette smoking is the leading cause of preventable deaths worldwide, and nicotine, the
primary psychoactive constituent in tobacco, drives sustained use. The behavioral actions of …
primary psychoactive constituent in tobacco, drives sustained use. The behavioral actions of …
Characterization of a novel nornicotine-degrading strain Mycolicibacterium sp. SMGY-1XX from a nornicotine-degrading consortium and preliminary elucidation of its …
B Dang, W Jia, S Ma, X Zhang, Y Huang… - Journal of Hazardous …, 2023 - Elsevier
Nicotine and nornicotine are all toxic alkaloids involved in the formation of carcinogenic
tobacco-specific nitrosamines. Microbes play an important role in removing these toxic …
tobacco-specific nitrosamines. Microbes play an important role in removing these toxic …
Effects of nicotine and minor tobacco alkaloids on intracranial-self-stimulation in rats
AC Harris, L Tally, P Muelken, A Banal… - Drug and alcohol …, 2015 - Elsevier
Background While nicotine is the primary addictive compound in tobacco, other tobacco
constituents including minor alkaloids (eg, nornicotine, anabasine) may also contribute to …
constituents including minor alkaloids (eg, nornicotine, anabasine) may also contribute to …
Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs
Dependence on opioids and the number of opioid overdose deaths are serious and
escalating public health problems, but medication-assisted treatments for opioid addiction …
escalating public health problems, but medication-assisted treatments for opioid addiction …
Effects of the GLP‐1 agonist Exendin‐4 on intravenous ethanol self‐administration in mice
G Sørensen, SB Caine… - Alcoholism: Clinical and …, 2016 - Wiley Online Library
Background Glucagon‐like peptide 1 (GLP‐1) receptor agonists have been shown to
decrease ethanol (EtOH) drinking in rodent assays. The GLP‐1 system also powerfully …
decrease ethanol (EtOH) drinking in rodent assays. The GLP‐1 system also powerfully …
Development of a nicotine aerosol self-administration model in rats and the effects of e-liquid flavors
JA Marusich, MI Palmatier - Behavioural Pharmacology, 2023 - journals.lww.com
Electronic nicotine delivery system (ENDS) use is maintained by the positive reinforcement
associated with preferred flavors. These flavors become conditioned reinforcers through …
associated with preferred flavors. These flavors become conditioned reinforcers through …
Effects of MAO inhibition and a combination of minor alkaloids, β-carbolines, and acetaldehyde on nicotine self-administration in adult male rats
TT Smith, MB Schaff, LE Rupprecht… - Drug and alcohol …, 2015 - Elsevier
Introduction Although nicotine is the primary reinforcing constituent in cigarettes, there is
evidence that other constituents in cigarette smoke may interact with nicotine to reinforce …
evidence that other constituents in cigarette smoke may interact with nicotine to reinforce …
[HTML][HTML] Variable effects of nicotine, anabasine, and their interactions on parasitized bumble bees
Secondary metabolites in floral nectar have been shown to reduce parasite load in two
common bumble bee species. Previous studies on the effects of nectar secondary …
common bumble bee species. Previous studies on the effects of nectar secondary …
Route of administration effects on nicotine discrimination in female and male mice
TW Lefever, BF Thomas, AL Kovach, RW Snyder… - Drug and alcohol …, 2019 - Elsevier
Background Use of electronic cigarettes (e-cigarettes) has increased exponentially since
their appearance on the US market around 2007. To provide preclinical models of vaping …
their appearance on the US market around 2007. To provide preclinical models of vaping …